What is alirocumab (Praluent) used for?
Alirocumab (brand name Praluent) is a prescription medicine used to lower low-density lipoprotein cholesterol (LDL-C) in patients with high cholesterol. It is commonly used in people with familial hypercholesterolemia or established cardiovascular disease, especially when LDL-C goals are not met with diet and other cholesterol-lowering therapies.
How does Praluent (alirocumab) work?
Praluent is a PCSK9 inhibitor. By blocking PCSK9, it helps increase the liver’s ability to remove LDL cholesterol from the blood, which lowers LDL-C levels.
Who can take Praluent?
Praluent is used for cholesterol lowering in appropriate patient groups where additional LDL-C reduction is needed. The exact eligibility depends on the condition being treated and how the medication fits with a patient’s current lipid-lowering regimen (for example, use with statins and/or other therapies when applicable).
How is Praluent given (dose schedule)?
Praluent is administered by subcutaneous injection. Common dosing patterns for PCSK9 inhibitors are every two weeks and, in some cases, every four weeks, depending on the prescribed dose and treatment plan.
What side effects are patients asking about?
Common concerns with PCSK9 inhibitors include injection-site reactions. Patients also ask about allergic reactions and other tolerability issues typical of injectable biologic therapies. If you’re evaluating risk for a specific patient, it’s important to review the full prescribing information and discuss prior hypersensitivity history with a clinician.
What’s the competitive landscape versus other cholesterol injections?
Praluent competes in the PCSK9 inhibitor class with evolocumab (Repatha). Both target PCSK9, but they can differ in dosing schedules, approved indications, and patient insurance coverage.
Is there a patent or exclusivity timeline for Praluent?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Praluent and can help you check when key protections may expire. You can search Praluent on DrugPatentWatch here: https://www.drugpatentwatch.com/
Sources cited: DrugPatentWatch.com (for patent/exclusivity lookup).